Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-22T18:43:53.087Z Has data issue: false hasContentIssue false
  • English
  • Français

Placebo response in schizophrenia: discussion

Published online by Cambridge University Press:  16 April 2020

SLE Heylen
SLE Heylen*
Affiliation:
Janssen Research Foundation, Turnhoutseweg 30, B-2340Beerse, Belgium
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Discussion
Information
European Psychiatry , Volume 9 , Issue 3: European Committee for Standardisation of Clinical Trials with Psychotropics, ECST Strasbourg Forum III. 10-11 June 1993, Strasbourg, France , 1994 , pp. 121 - 122
Copyright
Copyright © Elsevier, Paris 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Angst, JBech, PBobon, Det al. Report on the third consensus conference on the methodology of clinical trials with antipsychotic drugs. Pharmacopsychiatry (Stuttgart) 1991;24:149–52CrossRefGoogle ScholarPubMed
Chouinard, GA placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta Psychiatr Scand 1990;82(suppl 358):111–9CrossRefGoogle Scholar
Chouinard, GJones, BRemington, Get al. A Canadian multicenter placebo-controlled study of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993:13:25–40CrossRefGoogle ScholarPubMed
Curson, DAHirsch, SRPlatt, SDBamber, RWBarnes, TREDoes short term placebo treatment of chronic schizophrenia produce long-term harm? Br Med J 1986:293:726–8CrossRefGoogle ScholarPubMed
Heinrichs, DWHanlon, TECarpenter, WTThe Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophren Bull 1984:10:388–96CrossRefGoogle ScholarPubMed
Hirsch, SRBarnes, TRETesting the efficacy of new neuroleptic drugs. In:Benkert, OMaier, WRickels, K eds. Methodology of the Evaluation of Psychotropic Drugs. Psychopharmacology Series 8, Berlin: Springer Verlag, 1990Google Scholar
Submit a response

Comments

No Comments have been published for this article.